237 related articles for article (PubMed ID: 29020544)
1. Is There a 'Right to Try' Experimental Therapies? Ethical Criteria for Selecting Patients With Spinal Muscular Atrophy to Receive Nusinersen in an Expanded Access Program.
Jecker NS
Am J Bioeth; 2017 Oct; 17(10):70-71. PubMed ID: 29020544
[No Abstract] [Full Text] [Related]
2. Fairness and Transparency in an Expanded Access Program: Allocation of the Only Treatment for SMA1.
Burgart AM; Collier J; Cho MK
Am J Bioeth; 2017 Oct; 17(10):71-73. PubMed ID: 29020542
[No Abstract] [Full Text] [Related]
3. Expanded Access for Nusinersen in Patients With Spinal Muscular Atropy: Negotiating Limited Data, Limited Alternative Treatments, and Limited Hospital Resources.
Wilfond BS; Morales C; Taylor HA
Am J Bioeth; 2017 Oct; 17(10):66-67. PubMed ID: 29020560
[No Abstract] [Full Text] [Related]
4. Implementing a Global Expanded Access Program (EAP) for Infantile-Onset Spinal Muscular Atrophy (Type I): Understanding the Imperative, Impact and Challenges.
Yong J; Moffett M; Lucas S
J Neuromuscul Dis; 2019; 6(2):227-231. PubMed ID: 31127730
[TBL] [Abstract][Full Text] [Related]
5. Hard Choices for Vulnerable Patients: Some Lessons Learned That May Apply.
Kearns L; Caplan AL
Am J Bioeth; 2017 Oct; 17(10):68-69. PubMed ID: 29020543
[No Abstract] [Full Text] [Related]
6. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
7. [Nusinersen in SMA children: evolution or revolution? - Clinical use of innovative, repurposed or off-label therapies: a real life experience (2)].
Richelme C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():22-25. PubMed ID: 30943156
[No Abstract] [Full Text] [Related]
8. Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy.
Salmin F; Albamonte E; Morettini V; Gagliano N; Mercuri E; Sansone VA
Muscle Nerve; 2019 Jun; 59(6):E42-E44. PubMed ID: 30811610
[No Abstract] [Full Text] [Related]
9. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
[TBL] [Abstract][Full Text] [Related]
10. Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration.
Gerrity MS; Prasad V; Obley AJ
JAMA Intern Med; 2018 Jun; 178(6):743-744. PubMed ID: 29710299
[No Abstract] [Full Text] [Related]
11. Nusinersen for SMA: expanded access programme.
Farrar MA; Teoh HL; Carey KA; Cairns A; Forbes R; Herbert K; Holland S; Jones KJ; Menezes MP; Morrison M; Munro K; Villano D; Webster R; Woodcock IR; Yiu EM; Sampaio H; Ryan MM
J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):937-942. PubMed ID: 29549190
[TBL] [Abstract][Full Text] [Related]
12. Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience.
Messina S; Pane M; Sansone V; Bruno C; Catteruccia M; Vita G; Palermo C; Albamonte E; Pedemonte M; Bertini E; Binetti L; Mercuri E;
Neuromuscul Disord; 2017 Dec; 27(12):1084-1086. PubMed ID: 29132728
[No Abstract] [Full Text] [Related]
13. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
14. [Spinal muscular atrophy treated with nusinersen].
Boesen MS; Albrechtsen S; Born AP
Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618374
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
[No Abstract] [Full Text] [Related]
16. Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy.
LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
Am J Respir Crit Care Med; 2019 Dec; 200(12):1547-1550. PubMed ID: 31433957
[No Abstract] [Full Text] [Related]
17. Right-to-Try Investigational Therapies for Incurable Disorders.
Simmons Z
Continuum (Minneap Minn); 2017 Oct; 23(5, Peripheral Nerve and Motor Neuron Disorders):1451-1457. PubMed ID: 28968371
[TBL] [Abstract][Full Text] [Related]
18. Putting our best foot forward: Clinical, treatment-based and ethical considerations of nusinersen therapy in Canada for spinal muscular atrophy.
Vukovic S; McAdam L; Zlotnik-Shaul R; Amin R
J Paediatr Child Health; 2019 Jan; 55(1):18-24. PubMed ID: 30246272
[TBL] [Abstract][Full Text] [Related]
19. Spinal muscular atrophy 5Q - Treatment with nusinersen.
; Silvinato A; Bernardo WM
Rev Assoc Med Bras (1992); 2018 Jun; 64(6):484-491. PubMed ID: 30304304
[TBL] [Abstract][Full Text] [Related]
20. Nusinersen for Type 1 Spinal Muscular Atrophy: A Father's Perspective.
Hoot NR
Pediatrics; 2019 Oct; 144(4):. PubMed ID: 31506303
[No Abstract] [Full Text] [Related]
[Next] [New Search]
